UK markets open in 4 hours 7 minutes

Celyad SA (CYAD)

NasdaqGM - NasdaqGM Delayed price. Currency in USD
Add to watchlist
1.0000-0.0100 (-0.99%)
At close: 10:49AM EST

Celyad SA

Axis Business Park
Rue Edouard Belin 2
Mont-Saint-Guibert 1435
Belgium
32 1 039 41 00
https://www.celyad.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees95

Key executives

NameTitlePayExercisedYear born
Mr. Michel E. J. Lussier BME, M.B.A., M.S., MBA, MS BMECo-Founder, CFO, Interim CEO & Director85.34kN/A1956
Mr. David GeorgesVP of Fin. & Admin.N/AN/AN/A
Sara ZelkovicCommunications & Investor Relations DirectorN/AN/AN/A
Mr. Philippe NobelsChief HR Officer & VP of HRN/AN/A1966
Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D.Chief Medical OfficerN/AN/A1965
Ms. An PhanHead of LegalN/AN/AN/A
Mr. Hannes IserentantHead of Intellectual PropertyN/AN/AN/A
Dr. Frédéric LehmannVP of Clinical Devel. & Medical AffairsN/AN/A1964
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Corporate governance

Celyad SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.